Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - Crinetics Pharmaceuticals, Inc. (CRNX) reported a quarterly loss of $1.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.27, and compared to a loss of $0.96 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $0.14 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 94.7%, while revenues were zero a year ago [2] - The stock has underperformed, losing about 16.8% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] Financial Performance - The earnings surprise for the recent quarter was -8.66%, and the company has only surpassed consensus EPS estimates once in the last four quarters [2][3] - The current consensus EPS estimate for the upcoming quarter is -$1.30 on revenues of $3.25 million, and for the current fiscal year, it is -$4.85 on revenues of $4.98 million [7] Market Outlook - The company's stock is currently rated Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] - The outlook for the Medical - Drugs industry, where Crinetics operates, is relatively strong, ranking in the top 39% of over 250 Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]